CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Comparative Assessment of Coverage Criteria for Biologic Disease-Modifying Antirheumatic Drugs Across Canadian Public Drug Plans: An Environmental Scan

Last updated: May 5, 2020
Project Number: ES0351-000
Product Line: Environmental Scans
Result type: Report

CADTH conducted an Environmental Scan to better understand the similarities and differences in the current public drug programs criteria for accessing biologic drugs in the treatment of rheumatoid arthritis (RA) in Canada.

The specific objective was to identify and to compare existing criteria for reimbursing biologic drugs in RA across Canadian public formularies.

The findings of this Environmental Scan support a broader policy question regarding the harmonization of public coverage policies for biologics in Canada for patients with RA.